University of Colorado Cancer Center


 

ES-SCLC Paradigm Change Following IMpower133 and CASPIAN Trials: What Is the Role of Durvalumab in 1L Setting? How Does the Addition of Atezolizumab to CP/ET Affect Patient Outcomes?

632 views
August 17, 2020
Comments 0
Login to view comments. Click here to Login